Abstract Context Hemoglobin A1c (A1c) and fasting plasma glucose (FPG) miss diabetes diagnosis in many individuals, but the alternative, oral glucose tolerance testing (OGTT), is difficult to obtain. Objective This work aimed to develop and validate a model to identify diabetes missed by A1c and FPG but detected by OGT...
A. Hutchison, Simar Narula, B. Faubert et al.· Journal of the Endocrine Soc...· 0 citations
The recent conditional US Food and Drug Administration (FDA) approval of two therapies, resmetirom (Rezdiffra) and semaglutide (Wegovy), marks the first time clinicians have pharmacological therapy for metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis (F2-F3) without cirrhosis, a disease...
Maria Mironova, Vlad Ratziu, M. Rinella et al.· Gut· 0 citations
Fibrosis improvement in MASH is attainable by available drugs with further promise from emerging therapies, and a rich therapeutic pipeline with the promise of combination regimens and increased focus non-invasive endpoints suggests that the future looks bright for patients living with fibrotic MASH.
